UCLA Health joins nationwide clinical trial for acute myeloid leukemia

UCLA Health has joined an important national clinical trial that uses genetic testing to match people who have acute myeloid leukemia, or AML, with new therapies. UCLA ’s hospital system is the first in California to offer people the opportunity to participate.The Beat AML Master Trial will evaluate a precision-based medicine approach to treating the disease; it will allow people with the disease to have immediate access to new treatments that are currently in development without having to try more traditional approaches first. The approach could streamline a patient ’s course of treatment and, ultimately, save more lives.Acute myeloid leukemia, which affects 20,000 Americans annually, is responsible for more than 10,000 deaths a year, making it the most lethal form of blood cancer.  “The ability to quickly connect patients with investigational drug therapies based on the individual genetic markers of their disease is the essence of precision medicine,” said Dr. Gary Schiller, the principal investigator in the UCLA arm of the trial and a member of theUCLA Jonsson Comprehensive Cancer Center. “We hope that this becomes a turning point in how we treat this disease, which is, in many ways, multiple diseases with multiple mutations involved.”The trial — for people 60 and older who are newly diagnosed with acute myeloid leukemia — is sponsored by the Leukemia&Lymphoma Society and is divided into nine treatment arms based on ...
Source: UCLA Newsroom: Health Sciences - Category: Universities & Medical Training Source Type: news

Related Links:

Cancer is one of the leading causes for the morbidity and mortality worldwide. Although substantial studies have been conducted theoretically and experimentally in recent years, it is still a challenge to expl...
Source: BMC Systems Biology - Category: Molecular Biology Authors: Tags: Software Source Type: research
Lab Chip, 2018, Accepted Manuscript DOI: 10.1039/C8LC01071D, PaperPeng Zhang, Jennifer Crow, Divya Jyothi Lella, Xin Zhou, Glenson Samuel, Andrew K Godwin, Yong Zeng Extracellular vesicles (EVs) present a promising liquid biopsy for cancer diagnosis. However, it remains a daunting challenge to quantitatively measure molecular contents of EVs including tumor-associated mRNAs. Herein, we report... The content of this RSS Feed (c) The Royal Society of Chemistry
Source: RSC - Lab Chip latest articles - Category: Chemistry Authors: Source Type: research
Dalton Trans., 2018, Accepted Manuscript DOI: 10.1039/C8DT03948H, CommunicationYuanyuan You, Ni Wang, Lizhen He, Changzheng Shi, Dong Zhang, Yiyong Liu, Liangping Luo, Tianfeng Chen Herein we design and synthesize a cell penetration peptide- and cancer-targeted molecule-functionalized multi-walled carbon nanotube for precise orthotopic glioma therapy. This nanosystem demonstrates improved cancer recognition, blood-brain barrier (BBB) penetration,... The content of this RSS Feed (c) The Royal Society of Chemistry
Source: RSC - Dalton Trans. latest articles - Category: Chemistry Authors: Source Type: research
McLean, in his letter to the editor, suggested that the conclusions made in our manuscript1 may be the result of Simpson's paradox. In other words, he believes that our results would have been different had we combined the US Sarcoma Collaborative and National Cancer Database (NCDB) patients and analyzed them collectively.
Source: Journal of the American College of Surgeons - Category: Surgery Authors: Tags: Letter Source Type: research
MR imaging has been increasingly getting attention for the evaluation of bladder cancer. Recent studies have been promising for the staging performance of MR imaging in the bladder cancer, although its specific role has not been established yet. Additionally, the use of hybrid imaging combining PET with MR imaging could have the potential to increase its accuracy, although more research studies are needed.
Source: Magnetic Resonance Imaging Clinics of North America - Category: Radiology Authors: Source Type: research
We present the technical and interpretation skills required to use MR urography and CTU effectively.
Source: Magnetic Resonance Imaging Clinics of North America - Category: Radiology Authors: Source Type: research
Renal tumors encompass a heterogeneous disease spectrum, which confounds patient management and treatment. Percutaneous biopsy is limited by an inability to sample every part of the tumor. Radiomics may provide detail beyond what can be achieved from human interpretation. Understanding what new technologies offer will allow radiologists to play a greater role in caring for patients with renal cell carcinoma. In this article, we review the use of radiomics in renal cell carcinoma, in both the pretreatment assessment of renal masses and posttreatment evaluation of renal cell carcinoma, with special emphasis on the use of mul...
Source: Magnetic Resonance Imaging Clinics of North America - Category: Radiology Authors: Source Type: research
Multiparametric MR imaging is being used for prostate cancer diagnosis. However, many cancers are missed and the performance needs to improve before it can be used for population-level screening. We can expect standardization of multiparametric MR imaging and increased use of quantitative multiparametric MR imaging, which will lead to more reproducible results and improved interpretation. The development and integration of new acquisition techniques and use of artificial intelligence for image interpretation can lead to implementation of new clinical MR methods. These will lead to increased adoption of multiparametric MR i...
Source: Magnetic Resonance Imaging Clinics of North America - Category: Radiology Authors: Source Type: research
Acute Myeloid Leukemia (AML) is an aggressive malignancy that is treated using intensive cytotoxic chemotherapeutic regimens. There are limited alternative therapeutic options once the disease becomes refractory to chemotherapeutic treatment. CD33 is expressed on the surface of the vast majority of AML blasts and cells in chronic myeloid leukemia-blast crisis (CML-BC) – and is a well-validated immunotherapeutic target.  CD33 is also aberrantly expressed on a subset of T cell acute lymphoblastic leukemias (ALLs). Normal tissue expression is restricted to normal myeloid cells. Treatment of pre-B cell ALL and lymph...
Source: NIH OTT Licensing Opportunities - Category: Research Authors: Source Type: research
Conclusion This is the first attempt to provide a glimpse on the pattern and distribution of HMs among AYA in Bangladesh. Future studies are essential to get a better insight on the epidemiology, biology, potential risk factors and treatment outcomes for the AYA age group.
Source: Cancer Epidemiology - Category: Cancer & Oncology Source Type: research
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Acute Myeloid Leukemia | Cancer | Cancer & Oncology | Cancer in Adolescents | Cancer in Young Adults | Cancer Therapy | Child Development | Children | Clinical Trials | Food and Drug Administration (FDA) | Gene Therapy | Genetics | Hematology | Hospitals | Learning | Leukemia | Lymphoma | Research | Universities & Medical Training